Last updated: October 31, 2026
ZINBRYTA, the brand name for daclizumab, has no active commercial market. Biogen and AbbVie withdrew the multiple-sclerosis biologic globally after reports of severe inflammatory brain disorders, including encephalitis, meningoencephalitis, and other immune-mediated events. The European Union revoked its authorization, and the U.S. Food and Drug Administration ended its regulatory availability in 2018.[1][2]
The product’s commercial trajectory was short. ZINBRYTA generated limited revenue after its 2016 launch, failed to establish a durable position against oral and infused multiple-sclerosis therapies, and was removed before it could reach mature-market scale. Current value lies primarily in historical competitive analysis, pharmacovigilance, and discontinued-product portfolio assessment rather than in future sales, generic entry, or licensing potential.
What was ZINBRYTA and who marketed daclizumab?
ZINBRYTA was a humanized monoclonal antibody targeting the interleukin-2 receptor alpha subunit, also known as CD25. It was administered as a subcutaneous injection once every four weeks for adults with relapsing forms of multiple sclerosis.
Biogen and AbbVie developed and commercialized ZINBRYTA. AbbVie obtained rights through its acquisition of Pharmacyclics? No. The relevant commercial relationship was between Biogen and AbbVie, with Biogen responsible for commercialization in the United States and AbbVie involved in development and commercialization rights.[3]
Daclizumab had earlier been marketed as Zenapax for prevention of acute organ-transplant rejection. Roche developed Zenapax, but that product was withdrawn from the market in 2009 after limited commercial demand. The later ZINBRYTA product used a modified development and regulatory strategy for multiple sclerosis.
ZINBRYTA product profile
| Attribute |
ZINBRYTA |
| Active ingredient |
Daclizumab |
| Drug class |
Humanized monoclonal antibody |
| Target |
CD25, the interleukin-2 receptor alpha subunit |
| Route |
Subcutaneous injection |
| Dosing |
150 mg once every four weeks |
| Initial FDA approval |
May 27, 2016 |
| Initial indication |
Relapsing forms of multiple sclerosis |
| U.S. commercial sponsors |
Biogen and AbbVie |
| EU authorization |
Granted in 2016; withdrawn in 2018 |
| Global status |
Withdrawn and no longer marketed |
The FDA approved ZINBRYTA for patients who had an inadequate response to two or more multiple-sclerosis therapies. The label included a boxed warning for serious liver injury and required a restricted distribution and monitoring program.[1]
When did ZINBRYTA lose exclusivity and commercial availability?
ZINBRYTA lost commercial availability in 2018, before patent expiry became the primary market event. Biogen and AbbVie announced a global voluntary withdrawal in March 2018. The decision followed reports of serious inflammatory brain disorders and other severe immune-mediated adverse events.[2]
ZINBRYTA exclusivity timeline
| Date |
Event |
| May 27, 2016 |
FDA approved ZINBRYTA for relapsing forms of multiple sclerosis |
| 2016 |
European Commission granted marketing authorization |
| 2017 |
Additional serious safety reports emerged, including encephalitis and meningoencephalitis |
| March 2018 |
Biogen and AbbVie announced global voluntary withdrawal |
| April 2018 |
European Medicines Agency recommended suspension and withdrawal |
| May 2018 |
FDA announced voluntary withdrawal and termination of U.S. distribution |
| 2018 onward |
No commercial ZINBRYTA market remained |
The FDA stated that the benefits of ZINBRYTA no longer outweighed its risks because of severe liver injury and immune-mediated adverse reactions. The FDA also advised patients and physicians to stop initiating treatment and transition patients to alternative therapies.[1]
What was the patent expiration date for ZINBRYTA?
A single commercially decisive ZINBRYTA patent expiration date did not determine market entry. The product was withdrawn years before ordinary biosimilar or follow-on competition could become a practical issue.
Daclizumab had earlier antibody and manufacturing intellectual property associated with its development as Zenapax and later as ZINBRYTA. Some early composition and antibody-related patents would have had limited remaining life by the 2016 launch. Product-specific formulation, dosing, and method-of-use rights may have extended beyond core molecule patents, but those rights did not create a viable commercial barrier after withdrawal.
No authorized U.S. biosimilar or interchangeable product has been commercialized for ZINBRYTA. No active branded market exists against which a Paragraph IV generic challenge would have economic value.
How did ZINBRYTA’s financial trajectory develop?
ZINBRYTA’s revenue ramp was modest and short-lived. The product entered a crowded multiple-sclerosis market dominated by established injectable therapies, oral drugs, and high-efficacy infusions. Its boxed warning, monitoring requirements, restricted distribution system, and limited treatment positioning constrained uptake.
Biogen reported ZINBRYTA product revenue in its annual filings during the short commercial period. Reported revenue rose after launch but remained small relative to Biogen’s major multiple-sclerosis brands, including TECFIDERA, TYSABRI, AVONEX, and PLEGRIDY.[3][4]
Estimated commercial trajectory based on company disclosures
| Period |
Commercial position |
Financial interpretation |
| 2016 |
U.S. launch and early EU commercialization |
Initial revenue contribution remained limited |
| 2017 |
Wider market exposure but restricted label and safety concerns |
Revenue remained immaterial relative to Biogen’s core MS portfolio |
| Early 2018 |
Safety-driven withdrawal process |
New-patient starts declined sharply |
| Late 2018 onward |
Product discontinued |
Recurring product revenue ended |
Biogen’s filings treated ZINBRYTA as a small product within a much larger multiple-sclerosis portfolio. The withdrawal reduced future revenue but did not materially alter Biogen’s overall financial profile because the company’s revenue base was concentrated in higher-selling products.[3][4]
Why did ZINBRYTA fail to scale financially?
Four factors limited commercial expansion:
- The label positioned ZINBRYTA for patients who had failed multiple prior therapies.
- Liver monitoring created operational friction for physicians and patients.
- Competing products offered established efficacy, oral dosing, or broader treatment familiarity.
- Serious post-marketing safety events rapidly changed the benefit-risk assessment.
ZINBRYTA’s value proposition was therefore narrow before withdrawal. It offered monthly subcutaneous dosing, but that convenience did not offset the monitoring burden and safety concerns for a large segment of prescribers.
What FDA regulatory status does ZINBRYTA have?
ZINBRYTA is not an available FDA-approved treatment. The FDA-approved product was withdrawn from the U.S. market in 2018 at the request of Biogen and AbbVie.[1]
The FDA’s action followed reports of serious neurologic and immune-mediated adverse events. Reported conditions included:
- Encephalitis
- Meningoencephalitis
- Acute disseminated encephalomyelitis
- Other inflammatory brain disorders
- Severe liver injury
- Serious skin and lymph-node reactions
Before withdrawal, ZINBRYTA was subject to a Risk Evaluation and Mitigation Strategy, or REMS, involving prescriber certification, pharmacy controls, patient enrollment, liver-function monitoring, and periodic assessment of treatment risk.[1]
What was the European regulatory status of ZINBRYTA?
The European Medicines Agency recommended suspension of ZINBRYTA’s marketing authorization in March 2018 and recommended its withdrawal after reviewing reports of serious inflammatory brain disorders and other severe immune reactions.[2]
The European Commission subsequently withdrew the marketing authorization. ZINBRYTA is not an active European multiple-sclerosis treatment and is not available for routine prescribing.
What safety issues drove ZINBRYTA’s market withdrawal?
The principal market-disrupting issue was the emergence of severe inflammatory brain disease. The reports were clinically serious, sometimes fatal, and difficult to reconcile with continued broad use in a chronic disease population.
The product already carried a boxed warning for potentially fatal liver injury. The later neurological safety signal added a second major risk domain. Regulators concluded that the cumulative safety profile was unacceptable relative to available multiple-sclerosis alternatives.[1][2]
The safety profile affected the product in three commercial stages:
Pre-launch and early launch
The product entered the market with prominent liver-related restrictions. Physicians had to evaluate liver function before and during treatment, and treatment initiation was restricted to controlled channels.
Post-marketing surveillance
Cases of encephalitis and other immune-mediated neurological conditions increased regulatory scrutiny. The events were uncommon but clinically severe.
Withdrawal
Once the manufacturers announced withdrawal, continued patient initiation stopped. Existing patients were advised to discontinue or transition to other therapies under medical supervision.
What patents protected ZINBRYTA?
ZINBRYTA’s intellectual-property position likely included several categories of rights rather than one commercially decisive patent:
- Antibody and anti-CD25 composition patents
- Humanization and sequence-related patent claims
- Pharmaceutical composition patents
- Subcutaneous dosing patents
- Multiple-sclerosis method-of-use claims
- Manufacturing and cell-culture technology
- Formulation and stability rights
The underlying daclizumab molecule had a long development history predating ZINBRYTA. That history reduced the expected remaining patent life for early molecule and antibody claims by the time of the 2016 approval.
Were there formulation patents for ZINBRYTA?
ZINBRYTA was supplied as a prefilled syringe for subcutaneous administration. Formulation and container-closure rights could have covered protein concentration, excipients, stability, storage, and delivery presentation. Those rights would have been relevant to follow-on competition if the product had remained commercially active.
They did not create meaningful post-withdrawal value because a biosimilar entrant would have had no established branded market to penetrate.
Were there method-of-use patents for ZINBRYTA?
Potential method-of-use claims could have covered treatment of relapsing multiple sclerosis, patient selection, dosing intervals, or use after inadequate response to other therapies. The approved label itself limited treatment to adults with relapsing forms of multiple sclerosis who had an inadequate response to two or more drugs.
Method-of-use protection would have been commercially secondary to regulatory safety concerns. A patent does not preserve a market when the reference product has been withdrawn for safety reasons.
Did ZINBRYTA face Paragraph IV challenges or biosimilar competition?
No commercially significant Paragraph IV challenge became associated with ZINBRYTA before withdrawal. Paragraph IV litigation is generally relevant to an active small-molecule product with substantial sales and an ANDA pathway. ZINBRYTA was a biologic, so a follow-on competitor would have used the Public Health Service Act biosimilar pathway rather than the traditional ANDA pathway.
No FDA-approved biosimilar or interchangeable product has replaced ZINBRYTA. The practical barriers were:
- No continuing reference-product sales
- No stable prescribing base
- Significant safety concerns
- Limited commercial return
- Complex monoclonal-antibody manufacturing
- Regulatory and pharmacovigilance risk
A theoretical biosimilar could face manufacturing and analytical comparability challenges, but those barriers are commercially irrelevant without an active reference product.
What patent litigation and settlement agreements affected ZINBRYTA?
No major public patent litigation or Paragraph IV settlement defined the ZINBRYTA market. The principal legal and regulatory event was the product withdrawal, not a patent dispute.
There is no widely recognized commercial settlement that enabled generic or biosimilar entry. The product’s market ended through manufacturer and regulator action before a competitive-entry dispute could shape pricing.
How did ZINBRYTA compare with competing multiple-sclerosis drugs?
ZINBRYTA competed against treatments with stronger commercial infrastructure and broader physician familiarity. Relevant competitors included Biogen’s own products, such as TECFIDERA, TYSABRI, AVONEX, and PLEGRIDY, as well as Novartis’s GILENYA and later MAYZENT, Sanofi’s AUBAGIO, Teva’s COPAXONE, and Roche’s OCREVUS.
| Product |
Company |
Route or modality |
Commercial advantage over ZINBRYTA |
| TECFIDERA |
Biogen |
Oral small molecule |
Established use and large prescriber base |
| TYSABRI |
Biogen |
Intravenous antibody |
High-efficacy positioning |
| GILENYA |
Novartis |
Oral small molecule |
Oral administration and early market adoption |
| AUBAGIO |
Sanofi |
Oral small molecule |
Oral convenience |
| COPAXONE |
Teva |
Injectable |
Longstanding safety familiarity |
| OCREVUS |
Roche |
Intravenous antibody |
Strong efficacy positioning and twice-yearly dosing |
| ZINBRYTA |
Biogen/AbbVie |
Monthly subcutaneous antibody |
Monthly dosing, but significant safety and monitoring burden |
ZINBRYTA’s monthly administration was commercially attractive in isolation. The product could not compete effectively against therapies with more favorable benefit-risk profiles, stronger evidence bases, or lower monitoring burdens.
Which companies were challenging ZINBRYTA commercially?
The main competitive pressure came from established multiple-sclerosis manufacturers rather than generic or biosimilar companies. The relevant companies were:
- Biogen
- AbbVie
- Novartis
- Roche
- Sanofi
- Teva
- Merck KGaA
- Bristol Myers Squibb, through its multiple-sclerosis portfolio
The market was shifting toward oral therapies and high-efficacy infusions. ZINBRYTA’s positioning as a later-line injectable antibody left it exposed to both ends of the market: convenient oral drugs for patients seeking lower administration burden and high-efficacy infusions for patients requiring stronger disease control.
What revenue exposure did the ZINBRYTA withdrawal create?
ZINBRYTA’s direct revenue exposure was limited relative to Biogen’s total sales. The larger financial effects were indirect:
- Loss of future revenue growth from a newly launched biologic
- Write-offs or impairment of inventory and launch assets
- Disruption to commercial infrastructure
- Patient-transition and medical-affairs costs
- Reputational damage within multiple sclerosis
- Reduced value of related development and manufacturing investments
The withdrawal did not create the type of franchise-level revenue shock associated with a leading blockbuster. Biogen’s main exposure was opportunity cost: ZINBRYTA had been expected to contribute to the company’s multiple-sclerosis portfolio but never reached scale.
AbbVie’s exposure was also limited compared with its major immunology franchises. The product did not approach the commercial importance of HUMIRA, SKYRIZI, or RINVOQ.
How strong was the ZINBRYTA patent estate?
The patent estate was commercially weak after withdrawal, despite potentially covering multiple technical categories.
Strengths
- Biologic manufacturing is difficult to replicate.
- Antibody sequence, formulation, and process claims could complicate follow-on development.
- Method-of-use claims could have restricted labeled treatment pathways.
- Regulatory data and safety requirements added practical barriers.
Weaknesses
- The underlying antibody had an older development history.
- ZINBRYTA launched late in the product life cycle.
- The product required intensive safety monitoring.
- Withdrawal eliminated the commercial incentive for biosimilar development.
- No continuing branded market supported litigation or licensing value.
The estate should therefore be classified as technically layered but commercially impaired. Patent breadth could not compensate for regulatory failure and market exit.
What generic launch scenarios existed for ZINBRYTA?
There is no credible current generic or biosimilar launch scenario. Three theoretical scenarios existed:
- A biosimilar could have launched while ZINBRYTA remained marketed, subject to regulatory approval and interchangeability considerations.
- A follow-on daclizumab could have pursued a separate indication or formulation, but the safety history would have created major regulatory barriers.
- An improved anti-CD25 antibody could have been developed as a new molecular product, but it would not have been a straightforward ZINBRYTA replacement.
The third scenario would require new clinical evidence and a separate benefit-risk assessment. It would not rely simply on patent clearance.
What licensing value remains for daclizumab or ZINBRYTA assets?
The commercial licensing value of ZINBRYTA-specific rights is low. Potential residual value could exist in:
- Historical clinical data
- Anti-CD25 research tools
- Manufacturing know-how
- Abandoned formulation work
- Safety and immunology datasets
- Noncommercial academic research
A license focused on commercial relaunch would face substantial regulatory, liability, and reputational obstacles. A license for research use or platform learning would be more plausible than a license for therapeutic commercialization.
Key Takeaways
- ZINBRYTA was daclizumab, a monthly subcutaneous monoclonal antibody for relapsing multiple sclerosis.
- Biogen and AbbVie launched the product in 2016.
- The FDA approved ZINBRYTA with a boxed warning for severe liver injury and a restricted distribution program.
- Serious inflammatory brain disorders and other immune-mediated events led to global withdrawal in 2018.
- ZINBRYTA never reached mature commercial scale.
- No meaningful Paragraph IV litigation or biosimilar competition developed.
- No current FDA-approved ZINBRYTA product, biosimilar, or interchangeable product exists.
- The patent estate may have included composition, formulation, dosing, method-of-use, and manufacturing rights, but withdrawal removed its practical commercial value.
- The product’s financial impact was limited relative to Biogen’s major multiple-sclerosis brands.
- Any future commercial use of daclizumab would face substantial clinical, regulatory, liability, and market-access barriers.
FAQs
Is ZINBRYTA still available in the United States?
No. Biogen and AbbVie withdrew ZINBRYTA from the U.S. market in 2018 after serious safety reports, including inflammatory brain disorders and severe liver injury.[1]
Is daclizumab the same drug as Zenapax?
Yes. Zenapax and ZINBRYTA both contained daclizumab, but they were developed for different uses. Zenapax was used for prevention of acute organ-transplant rejection, while ZINBRYTA was approved for relapsing multiple sclerosis.
Can a company launch a biosimilar to ZINBRYTA?
A company could theoretically develop a follow-on daclizumab product, but no commercial biosimilar market exists. The withdrawal, safety history, limited reference-product value, and regulatory risk make a commercial launch unlikely.
Did ZINBRYTA cause Biogen’s broader multiple-sclerosis business to decline?
No. ZINBRYTA was a small product relative to Biogen’s leading multiple-sclerosis medicines. Its withdrawal reduced portfolio breadth and future opportunity but did not determine the performance of Biogen’s overall multiple-sclerosis business.
What replaced ZINBRYTA for patients with relapsing multiple sclerosis?
Patients were transitioned to other approved disease-modifying therapies selected according to disease activity, prior treatment, safety profile, comorbidities, administration preferences, and monitoring requirements. No single replacement product was designated as a direct regulatory substitute.
References
- U.S. Food and Drug Administration. (2018). FDA working with manufacturers to withdraw multiple sclerosis drug Zinbryta from the U.S. market. https://www.fda.gov
- European Medicines Agency. (2018). Zinbryta: EMA recommends withdrawal of marketing authorisation. https://www.ema.europa.eu
- Biogen Inc. (2018). 2017 annual report. U.S. Securities and Exchange Commission. https://www.sec.gov
- Biogen Inc. (2019). 2018 annual report. U.S. Securities and Exchange Commission. https://www.sec.gov
